Long-term sarilumab therapy for rheumatoid arthritis demonstrates no new safety outcomes regardless of concurrent use of conventional synthetic disease-modifying antirheumatic drugs, according to data published in Rheumatology.“Sarilumab is a human recombinant IgG1 monoclonal antibody that binds to both soluble and membrane-bound IL-6 receptors (IL-6R) to inhibit IL-6-mediated